Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib Andrew J. Piper-Vallillo and Lecia V.…
Cardiotossicità da biologici
-
-
Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy…
-
Cardiac risk in the treatment of breast cancer: assessment and management Antonis Valachis and Cecilia Nilsson Breast…
-
Cancer therapy and cardiovascular risk: focus on bevacizumab Panagiota Economopoulou, Athanasios Kotsakis, Ioannis Kapiris, and Nikolaos Kentepozidis…
-
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors…
-
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast…
-
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond Di Lisi D, Madonna R, Zito C,…
-
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy Harbeck, M. S. Ewer, M.…